We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.99B
1-Year Est. Return 737.95%
This Fund
S&P 500
This Quarter Est. Return
-3.14%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$1.73B
AUM Growth
-$549M
Cap. Flow
-$263M
Cap. Flow %
-15.18%
Top 10 Hldgs %
58.51%
Holding
67
New
10
Increased
11
Reduced
11
Closed
18

Top Buys

Rank Stock Value
1
RAPP
Rapport Therapeutics
RAPP
+$68.1M
2
AXSM icon
Axsome Therapeutics
AXSM
+$29.6M
3
ALMS
Alumis Inc
ALMS
+$28.6M
4
PCVX icon
Vaxcyte
PCVX
+$28.2M
5
CGEM icon
Cullinan Oncology
CGEM
+$24M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$107M
2
TARS icon
Tarsus Pharmaceuticals
TARS
+$55.1M
3
AUTL
Autolus Therapeutics
AUTL
+$42.2M
4
BBIO icon
BridgeBio Pharma
BBIO
+$36.8M
5
ALXO icon
ALX Oncology
ALXO
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
26
Cullinan Oncology
CGEM
$1.08B
$19.6M 1.13%
+1,125,000
New +$24M
RYTM icon
27
Rhythm Pharmaceuticals
RYTM
$7.45B
$19.5M 1.13%
475,000
-75,000
-14% -$2.99M
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
$19.4M 1.12%
1,182,563
– –
YMAB
29
DELISTED
Y-mAbs Therapeutics
YMAB
$17.5M 1.01%
+1,450,000
New +$19.6M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$17.4M 1%
+425,000
New +$12.2M
BMEA icon
31
Biomea Fusion
BMEA
$90.4M
$16.1M 0.93%
3,570,872
– –
CNTA
32
DELISTED
Centessa Pharmaceuticals
CNTA
$14.6M 0.84%
1,611,600
+1,050,000
+187% +$9.96M
TARS icon
33
Tarsus Pharmaceuticals
TARS
$2.67B
$13.6M 0.79%
500,000
-1,639,102
-77% -$55.1M
SLN
34
Silence Therapeutics
SLN
$526M
$11.9M 0.69%
625,000
– –
AVBP icon
35
ArriVent BioPharma
AVBP
$1.46B
$9.55M 0.55%
515,000
– –
ENGN icon
36
enGene Therapeutics
ENGN
$120M
$9.43M 0.54%
1,000,000
– –
KRRO icon
37
Korro Bio
KRRO
$162M
$9M 0.52%
265,826
-263,344
-50% -$14.6M
IDYA icon
38
IDEAYA Biosciences
IDYA
$3.49B
$8.6M 0.5%
245,000
-205,000
-46% -$8.12M
IBRX icon
39
PUT
ImmunityBio
IBRX
$7.4B
$7.9M 0.46%
+1,250,000
New +$8.24M
GHRS icon
40
GH Research
GHRS
$2.01B
$6.91M 0.4%
593,043
– –
LNTH icon
41
Lantheus
LNTH
$6.59B
$6.02M 0.35%
75,000
– –
STOK icon
42
Stoke Therapeutics
STOK
$2.02B
$5.77M 0.33%
427,163
– –
MRSN
43
DELISTED
Mersana Therapeutics
MRSN
$5.23M 0.3%
104,000
– –
NGNE icon
44
Neurogene
NGNE
$705M
$3.91M 0.23%
107,344
-431,370
-80% -$15.2M
SIGA icon
45
PUT
SIGA Technologies
SIGA
$227M
$3.79M 0.22%
+500,000
New +$4.07M
YARW
46
Yarrow Bioscience, Inc. Common Stock
YARW
$26.1M
$2.75M 0.16%
27,887
– –
CMPX icon
47
Compass Therapeutics
CMPX
$351M
$2.03M 0.12%
2,030,823
-3,529,477
-63% -$5.15M
VERV
48
DELISTED
Verve Therapeutics
VERV
$1.71M 0.1%
350,000
– –
RAPT
49
DELISTED
RAPT Therapeutics
RAPT
$1.52M 0.09%
62,094
– –
ALXO icon
50
ALX Oncology
ALXO
$265M
– –
-3,142,079
Closed -$35M
1
2
3

Similar funds

SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
RMCM
Reynders McVeigh Capital Management Boston, Massachusetts $1.98B AUM 23.37% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return

Cormorant Asset Management's Q2 2024 Portfolio in Review

As of Q2 2024, Cormorant Asset Management held 67 positions worth $1.73B, down 24% from $2.28B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Cormorant Asset Management withdrew a net $263M in Q2 2024, closing 18 positions and reducing 11 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $107M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.

Against the trend, Cormorant Asset Management opened a new position in Rapport Therapeutics worth $68.4M.

  • Cormorant Asset Management's largest Q2 2024 buy was Rapport Therapeutics: 2,940,283 shares worth $68.4M.
  • Cormorant Asset Management added most to Vaxcyte in Q2 2024, an estimated $28.2M increase.
  • Cormorant Asset Management's biggest Q2 2024 reduction was Tarsus Pharmaceuticals, cutting an estimated $55.1M.
  • Cormorant Asset Management fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $107M.
  • Cormorant Asset Management's ten largest holdings make up 59% of its $1.73B portfolio in Q2 2024.
  • Cormorant Asset Management opened 10 new positions and closed 18 in Q2 2024.
  • Cormorant Asset Management's portfolio value fell 24% quarter-over-quarter to $1.73B.

Based on Cormorant Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.